Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1,151 - 1,200 out of 6,641

Document Document Title
WO/2002/083700A2
Provided are compounds and compositions thereof that are useful for treating inflammation, particularly pulmonary inflammations including asthma and asthma-related pathologies such as allergy. Also provided are methods for using such com...  
WO/2002/083660A1
Drugs, foods, drinks and feeds containing as the active ingredient compounds having coumarin and/or chroman skeletons which have an effect of enhancing NGF production and thus are efficacious in treating, ameliorating or preventing disea...  
WO/2002/081480A1
The present invention relates to a compound of formula (I), which are useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by MRP1.  
WO/2002/081493A1
Novel 9-amino-14-membered macrolides and pharmaceutically-acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, a method for treati...  
WO/2002/079465A2
An isolated gene cluster of Micromonospora echinospora which codes for calicheamicin biosynthesis. The biosynthetic gene cluster contains genes encoding proteins and enzymes used in the biosynthetic production of calicheamicin, including...  
WO/2002/079150A2
The present invention provides combinatorial methods for rapidly generating a diverse library of glycorandomized structures, comprising incubating one or more aglycons and a pool of NDP-sugars in the presence of a glycosyltransferase. Th...  
WO/2002/076402A2
The invention provides conjugates of fatty amines and pharmaceutical agents useful in treating cancers, viruses, psychiatric disorders. Compositions, pharmaceutical preparations, and methods of preparations of the fatty amine-pharmaceuti...  
WO/2002/077004A1
Macrolide compounds produced by synthetic modification of factors produced by NRRL 30141 have insecticidal and acaricidal activity and are useful intermediates for preparing additional insecticidal and acaricidal compounds.  
WO/2002/077005A1
Macrolide compounds produced by culturing novel mutant Saccharopolyspora sp. strains have insecticidal and acaricidal activity and are useful intermediates for preparing spinosyn analogs.  
WO/2002/076473A1
The patent relates to quercetin, its preparation and the medicinal composition containing the same and their application for preventing or treating diseases related to 5HT14 receptor or neure damage, including preventing or treating Alze...  
WO2002038577A3
An extended release pharmaceutical composition comprised of an erythromycin derivative and non-polymer material for providing for extended release, in particular, a member selected from the group consisting of clays, long chain hydrocarb...  
WO/2002/072111A1
A dry, reconstitutable telithromycin suspension characterized in that it contains granules or granules comprising a core containing telithromycin which is optionally associated with at least one waxlike compound and optionally with at le...  
WO2002032919A3
Compounds having formula (I) are useful for treating bacterial infections while avoiding the concomitant liability of gastrointestinal intolerance. Compositions containing the compounds and methods of treatment using the compounds are al...  
WO2001063539A8
The invention relates to novel methods for using macrolide anti-infective agents. The macrolide anti-infective agents demonstrate antibacterial activity against multi-drug resistant strains of bacteria and, in particular, methicillin-res...  
WO/2002/069926A1
The invention relates to cosmetic formulations, pharmaceutical preparations, food products and food supplements containing flavonoid derivatives. The flavonoid derivatives act therein, for instance, as UV filter. Some flavonoid derivativ...  
WO2000077182A9
The invention relates to a halogenation method characterized in that a chemical compound is halogenated in the presence of halogenase and in that (a) said halogenase is coded in the sequence indicated in SEQ ID NO: 1 or in a sequence der...  
WO/2002/068442A1
A compound of formula wherein X?-¿ is an anion; n is 1, 2, 3 or 4; R¿1? is C¿1?-C¿12?alkyl, C¿3?-C¿8?cycloalkyl; or C¿2?-C¿12?alkenyl; R¿2? is hydrogen, unsubstituted or substituted C¿1?-C¿12?alkyl or C¿2?-C¿12?alkenyl; R¿3...  
WO/2002/068440A1
Glucopyranosyloxypyrazole derivatives represented by the following general formula (I) expressing an excellent human SGLT2 activity inhibitory effect and thus being useful as preventives or remedies for diseases caused by hyperglycemia s...  
WO/2002/068438A2
The invention relates to 9a-N[N'-(phenylsulfonyl)carbamoyl] derivatives of 9-deoxo-9-dihydro-9a-aza-homoerythromycin A and 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolid e A, novel semisynthetic macrolide antibiotics from t...  
WO/2002/068439A1
Glucopyranosyloxypyrazole derivatives represented by the following general formula (I) expressing an excellent human SGLT2 activity inhibitory effect and thus being useful as preventives or remedies for diseases caused by hyperglycemia s...  
WO2001087807A3
The present invention relates to a cost effective and industrially advantageous process for the selective methylation of a hydroxy group at the 6 position of erythromycin A derivatives.  
WO/2002/068441A2
What is described are a compound of formula (I) in which, R¿1? is C¿1?-C¿12?alkyl, C¿3?-C¿8?cycloalkyl or C¿2?-C¿12?alkenyl; R¿2? is H, unsubstituted or mono- to pentasubstituted C¿1?-C¿12?alkyl or unsubstituted or mono-to pent...  
WO/2002/066487A1
Bicyclic leucomycins and pharmacuetically acceptable compositions comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, a method for treating bacterial inf...  
WO/2002/064608A1
The present invention provides methods for purifying and using optically active isomers of erythromycin as well as compositions comprising such optically active isomers. Such optically active isomers having desired actions as an antibiot...  
WO/2002/064092A2
The present invention relates to in vitro methods for evaluating compounds that better correlate with therapeutic efficiency than evaluating compounds based on potency alone. In general, the inventive methods comprises: (i) determining a...  
WO/2002/064607A1
Novel 16-membered macrolide derivatives represented by the general formula (I) and being effective against erythromycin-resistant Gram-positive bacteria and so on; or pharmaceutically acceptable salts thereof: (I) wherein R is hydrogen, ...  
WO2000024907A9
Genetic engineering of the erythromycin polyketide synthase genes to effect combinatorial alterations of catalytic activities in the biosynthetic pathway can be used to generate a library of macrolides impractical to produce by chemical ...  
WO/2002/062813A1
A novel glycoside which contains as the aglycon an isomaltol represented by the formula (I) (I) (wherein Sug is a glucose residue or a sugar chain consisting of two or more glucose units); a physiologically active substance which compris...  
WO2001077134A3
Disclosed herein is a process for the preparation of erythromycin derivatives, or pharmaceutically acceptable salts thereof, which contain an optionally substituted propargyl group at the 6-O-position.  
WO/2002/060436A2
This invention provides a method for treating a Pin1-associated state in a subject including administering to a subject an effective amount of a fredericamycin A compound such that the Pin1-associated state is treated. In another aspect,...  
WO/2002/060912A1
Novel 14-Membered Macrolides derived from Leucomycins comprising a therapeutically effective amount of a compound of the invention in combination with a pharmaceutically acceptable carrier, a method for treating bacterial infections by a...  
WO2002032233A3
The use of aivlosin, as much or as a pharmacologically acceptable (non-toxic) derivative such as an acid addition salt, for the preparation of a veterinary medicament for the treatment or prophylaxis of diseases and infections of pigs an...  
WO/2002/058734A2
The present invention provides compositions, therapeutic combinations and methods including: (a) at least one sterol absorption inhibitor; and (b) at least one blood modifier, which can be useful for treating vascular conditions and lowe...  
WO/2002/057285A1
A fullerene derivative represented by the formula (I): (I) wherein A represents a residue of a monosaccharide or disaccharide, Alk represents a lower alkylene group, a group represented by the formula (X): (X) represents a fullerene resi...  
WO/2002/057286A2
Compounds of formula (I), and formula (II), or therapeutically acceptable salts or prodrugs thereof are useful as antibacterial agents. Methods to make the compounds, compositions containing the compounds, and methods of treatment using ...  
WO/2002/053573A1
Glucopyranosyloxypyrazole derivatives represented by the general formula (I) or pharmacologically acceptable salts thereof, which exibit human SGLT2 inhibiting activity, are improved in peroral absorbability, and are useful as preventive...  
WO/2002/051855A2
The present invention provides novel macrolide compounds of the formulas for the treatment of gastrointestinal motility disorders.  
WO/2002/050091A1
The present invention relates to 11,12 $g(g) lactone ketolides of formula (I) wherein R, R?1¿, R?2¿, R?3¿ are as defined herein and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their use...  
WO/2002/050093A2
An efficient deoximation technique for use in synthesis of erythromycin derivatives, involving aryl thioimine intermediates is disclosed. The aryl thioimine intermediates can be utilized in a method for protecting a ketone of a ketone-co...  
WO/2002/050092A1
The present invention relates to 11,12$g(g) lactone ketolides of formula (I), wherein R, R?1¿, R?2¿ and R?3¿ are as defined herein and pharmaceutically acceptable salts and solvates thereof, to process for their preparation and their ...  
WO2001083448A3
Chemotherapy of malignant tumors is seriously restricted by the fact that available cytostatics are often not capable of differentiating between normal and malignant tissue. The aim of the invention is therefore to improve the selectivit...  
WO/2002/048331A2
The present invention provides mutant nucleotidylyltransferases, such as E¿p?, having altered substrate specificity; methods for their production; and methods of producing nucleotide sugars, which utilize these nucleotidylyltransferases...  
WO/2002/046204A1
6-0-carbamoyl ketolide antibacterials of the formula: wherein R?1¿, R?2¿, R?3¿, R?4¿, R?5¿, R6, X, X', Y, and Y' are as described herein and in which the substituents have the meaning indicated in the description. These compounds ar...  
WO/2002/044193A1
The invention relates to a method for obtaining azaerythromycin of formula (I) from 6,9-iminoether of erythromycin A, which is catalytically reduced at low pressure (less than 5 bars) after adjusting the pH with an appropriate acid and u...  
WO2002000663A3
A novel class of antitumour compounds has been recognised based on the isolation from a new marine microbe, strain PO13-046, belonging to the genus Actinomadura sp.), of a compound designated IB-00208. The class of the formulae (I) or (I...  
WO/2002/042315A2
Azithromycin in the form of a monohydrate comprising from 4.0 % to 6.5 % of water, a process for its preparation and its use in pharmaceutical compositions.  
WO2001097778A3
Parenteral compositions of oil-coated-Amphotericin B in structured-emulsion form, having LD>50< of atleast 400mg/kg in mice and process for making the same have been described. The process essentially requires dispersing Amphotericin B i...  
WO2002009640A3
The present invention provides a stable form of azithromycin derivatives that act as antibiotics. These compound are in anhydrous form and have increased stability over the hydrated forms.  
WO/2002/040036A1
Drugs efficacious in preventing and treating endometriosis and uterine myoma are disclosed. The preventives or remedies for endometriosis and uterine myoma contain macrolide antibiotics as the active ingredient.  
WO/2002/038577A2
An extended release pharmaceutical composition comprised of an erythromycin derivative and non-polymer material for providing for extended release, in particular, a member selected from the group consisting of clays, long chain hydrocarb...  

Matches 1,151 - 1,200 out of 6,641